Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

Larimar Therapeutics, Inc.

Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.
Full-year 2025 net loss $165.7M ($2.27/sh) vs $80.6M ($1.32/sh) in 2024.
Cash & equivalents $136.9M at Dec 31, 2025; pro forma $244.5M after Feb 2026 $107.6M offering, runway into Q2 2027.
FDA granted Breakthrough Therapy Designation for nomlabofusp in FA; FDA alignment on FXN as surrogate endpoint.
Phase 3 confirmatory study screening to start Q2 2026; topline open-label data expected Q2 2026; BLA submission June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.